Oncotarget

Reviews:

Research progress of neuroblastoma related gene variations

Yanna Cao, Yan Jin, Jinpu Yu, Jingfu Wang, Jie Yan and Qiang Zhao _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:18444-18455. https://doi.org/10.18632/oncotarget.14408

Metrics: PDF 1853 views  |   HTML 2142 views  |   ?  


Abstract

Yanna Cao1,*, Yan Jin1,*, Jinpu Yu2, Jingfu Wang1, Jie Yan1 and Qiang Zhao1

1 Department of Pediatric Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, P.R. China

2 Department of Cancer Molecular Diagnostic Center, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy of Tianjin, Tianjin’s Clinical Research Center for Cancer, Tianjin, P.R. China

* These authors have contributed equally to this work

Correspondence to:

Qiang Zhao, email:

Jie Yan, email:

Keywords: neuroblastoma, gene, high throughput nucleotide sequencing

Received: October 12, 2016 Accepted: December 27, 2016 Published: December 31, 2016

Abstract

Neuroblastoma, the most common extracranial solid tumor among children, is an embryonal tumor originating from undifferentiated neural crest cell. Neuroblastomas are highly heterogeneous, represented by the wide range of clinical presentations and likelihood of cure, ranging from spontaneous regression to relentless progression despite rigorous multimodal treatments. Approximately, 50% of cases are high-risk with overall survival rates less than 40%. With the efforts to collect large numbers of clinically annotated specimens and the advancements in technologies, researchers have revealed numerous genetic alterations that may drive tumor growth. However, the most lack mutations in genes that are recurrently mutated, which inspires researchers to identify disrupted pathways instead of single mutated genes to unearth biological systems perturbed in neuroblastoma. Stratification of patients and target therapy based on their molecular signatures have been the center of focus. This review provides a comprehensive summary of the recent advances in identification of candidate genes variations, targeted approaches to high-risk neuroblastoma and evaluates the methods utilized for detection, which will provide new avenues to develop therapies and further genetic researches.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 14408